However, although FXR agonists have shown good clinical efficacy in the treatment of NAFLD/NASH, there is no definite clinical trial to confirm its benefit for cardiovascular disease. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.